1. Racial and sex differences in optimizing anticoagulation therapy for patients with atrial fibrillation
- Author
-
Mark H. Eckman, Ruth Wise, Anthony C. Leonard, Pete Baker, Rob Ireton, Brett M. Harnett, Estrelita Dixon, Bi Awosika, Chika Ezigbo, Matthew L. Flaherty, Adeboye Adejare, Carol Knochelmann, Rachael Mardis, Sharon Wright, Ashish Gummadi, Richard Becker, Daniel P. Schauer, Alexandru Costea, Dawn Kleindorfer, Heidi Sucharew, Amy Costanzo, Lora Anderson, and John Kues
- Subjects
Racial disparities ,Gender disparities ,Atrial fibrillation ,Anticoagulation therapy ,Stroke prevention ,Decision sciences ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Study objective: Atrial fibrillation (AF) is the most common cardiac rhythm disorder, responsible for 15 % of strokes in the United States. Studies continue to document underuse of anticoagulation therapy in minority populations and women. Our objective was to compare the proportion of AF patients by race and sex who were receiving non-optimal anticoagulation as determined by an Atrial Fibrillation Decision Support Tool (AFDST). Design, setting, and participants: Retrospective cohort study including 14,942 patients within University of Cincinnati Health Care system. Data were analyzed between November 18, 2020, and November 20, 2021. Main outcomes and measures: Discordance between current therapy and that recommended by the AFDST. Results: In our two-category analysis 6107 (41 %) received non-optimal anticoagulation therapy, defined as current treatment category ≠ AFDST-recommended treatment category. Non-optimal therapy was highest in Black (42 % [n = 712]) and women (42 % [n = 2668]) and lower in White (39 % [n = 4748]) and male (40 % [n = 3439]) patients. Compared with White patients, unadjusted and adjusted odds ratios of receiving non-optimal anticoagulant therapy for Black patients were 1.13; 95 % CI, 1.02–1.30, p = 0.02; and 1.17; 95%CI, 1.04–1.31, p = 0.01; respectively, and 1.10; 95 % CI 1.03–1.18, p = 0.005; and 1.36; 95 % CI, 1.25–1.47, p
- Published
- 2022
- Full Text
- View/download PDF